johnson & johnson news

Johnson & Johnson Dips On Q4 Earnings

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Seeking Alpha · 16h

Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ stock is a Buy.

AOL · 17h

Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings

Johnson & Johnson beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highligh

The Motley Fool on MSN · 20h

Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript

Operator Good morning and welcome to Johnson & Johnson's fourth quarter 2024 earnings conference call. All participants will be in a listen-only mode until the question-and-answer session of the conference.

Zacks.com on MSN · 19h

Johnson & Johnson (JNJ) Q4 Earnings and Revenues Top Estimates

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $2.29 per share a year ago. These figures are adjusted for non-recurring items.

US FDA approves new nasal spray for depression treatment

Fortune on MSN · 7h

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult population.

U.S. News & World Report · 15h

FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants,

Zacks.com on MSN · 16h

J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use

Johnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for Spravato (esketamine) as a monotherapy for adults living with treatment-resistant depression (TRD).

Bears officially announce Ben Johnson

Chicago Tribune on MSN · 6h

Brad Biggs: Guided by self-awareness, Ben Johnson is finally prepared for his role as head coach of the Bears

Ben Johnson launched into his virtual interview with the Chicago Bears leaving no question as to his intentions. “I want this job,” Johnson said, Chairman George McCaskey recalled. The feeling was mutual and the Bears agreed to terms with Johnson on Monday.

USA TODAY Sports on MSN · 13h

Chicago Bears' Ben Johnson becomes one of youngest head coaches in NFL. See where he ranks

The Bears introduce Ben Johnson as new head coach, continuing a trend started with Sean McVay. Johnson isn't the youngest in the NFL, but he's close.

The Washington Post · 1d

With Ben Johnson on the move to Chicago, 5 head coaching vacancies remain

Ben Johnson made a quick decision. Aaron Glenn could be next. With Johnson heading to Chicago and Mike Vrabel already in New England, five head coaching vacancies remain. The Jets, Saints, Jaguars, Raiders and Cowboys are still in the hunt.

18h

Johnson & Johnson says positioned for 5%-7% growth through 2030 and beyond

Says starting 2025 from a position of strength. Says invested ~$50B in R&D and M&A in 2024. Says continues to invest in R&D at ...

MassDevice19h

Johnson & Johnson MedTech sales grow 6.2% in 2025, driven by EP, Abiomed

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

20hon MSN

Johnson & Johnson posts Q4 beat as drug sales offset MedTech weakness

Johnson & Johnson (JNJ) traded flat after exceeding Street forecasts with its Q4 2024 results thanks mainly to its Innovative ...

Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Shareholders to Connect

NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Ben Johnson coaching tracker: Latest on Lions offensive coordinator, interview updates, teams interested

Lions offensive coordinator Ben Johnson is one of the most in-demand candidates for vacant head-coaching positions, thanks to ...

MarketBeat on MSN5d

Is Johnson & Johnson Stock Set to Reward Long-Term Holders?

Johnson & Johnson (NYSE: JNJ) stock is up 1.8% in the five days after the company announced its $14.6 billion acquisition of ...

Hold Rating for Johnson & Johnson Amid Modest Growth Outlook and Legal Uncertainties

In a report released today, Tim Anderson from Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research ...

6don MSN

Mike Johnson has a new headache in the narrowly divided House: From the Politics Desk

Johnson sent shockwaves around Capitol Hill when he decided to oust Rep. Mike Turner, R-Ohio — a staunch NATO supporter who ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results